Search

OBJECTIVES: Neuroendocrine tumors of the lungs are a clearly different group of tumors with definite ultrastructural, immunohistochemical, and molecular features. We reported and analyzed the incidence, clinicopathological features, surgery rates, responses to first-line therapy, and survival outcomes of this rare condition according to our lung cancer patient database. MATERIALS AND METHODS: We retrospectively collected the data of 62 patients who were histopathologically diagnosed with large cell neuroendocrine carcinoma of lung (LCNEC) between January 2010 and January 2016. RESULTS: The patients were predominantly (95%) men (male:female=59:3) with their average age being 60.3±8.6 years. Diagnosis was made by the fine-needle aspiration biopsy (NAB) in 7 patients, bronchoscopic transbronchial biopsy in 13, and surgery in 42. Nearly 43.5% of the patients presented with the tumor in the right upper lobe. Additionally, tumors of 46.8% patients could be observed in peripheral locations. Sixteen patients presented with stage 1, 17 with stage 2, 15 with stage 3, and 14 with stage 4. Median progression-free survival (PFS) was 29 months (SE: 12.2) (95% CI, 5.2-52.8 months). Progression-free survival (PFS) was significantly better in patients with low N, M0, early stage, p63 positive, and TTF-1 positive across the entire cohort. Overall survival (OS) was significantly better in patients with comparatively lower N, M0, low stage, and peripheral location. CONCLUSION: This study demonstrated a single-center experience with clinicopathologic factors and survival outcomes of LCNEC patients. [ABSTRACT FROM AUTHOR]

Objective: Age, sex, weight loss, lactate dehydrogenase (LDH) level, hemoglobin concentration, stage and ECOG performance status (PS) have been accepted as prognostic factors for patients with small cell lung cancer (SCLC). In our study, we aim to evaluate the relationship between prognostic factors and survival in patients with SCLC. Material and Method: A total of 106 patients with SCLC, between 2005 and 2008, were retrospectively analyzed. Results: The median age of patients at diagnosis was 59.3 and 89.6% of patients were male; 33.1% of patients were older than 65 years and 73 patients were younger than 65 years of age. 54 out of 106 patients had limited stage disease (LSD) (52.9%), and 48 had extended stage disease (ESD) (47.1%). The ratio of PS 0-1 and 2 patients were 77.3% and 22.7% respectively. 36% of them had high serum LDH level and 29.3% had low hemoglobin level. In our study, clinical response was achieved in 71.2% of patients. Overall median survival was 14.2 months. While median survival was 19.7 month in LSD, in ESD it was 9.1 months and stage was found to be prognostic factor in multivariate analysis (p=0.001). Multivariate analysis showed that there were no correlations among median survival and PS, LDH level, weight loss, sex, age (p>0.05). Conclusion: Although we found no relationship between prognostic factors and median survival and progression free survival, the patients with LSD had more prolonged OS than ESD. Whenever possible, more SCLC patients may be included in future clinical trials to detect the relationship between prognostic factors and overall survival time. [ABSTRACT FROM AUTHOR]